GlassScriptPhysician profile
Amy Seal
NPI 1477171627
$2,467.72
in general payments reported to CMS, 2019-2025
16 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $1,416 · 2023: $701 · 2024: $66.99 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $449.97 | 2022-2024 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.19 | 2022-2025 | Caplyta |
| Abbvie INC. | $364.00 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $270.15 | 2022-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $191.37 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $178.03 | 2021-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $130.74 | 2021-2023 | Austedo |
| Corium, LLC | $87.96 | 2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $74.43 | 2022-2023 | Invega Sustenna |
| Alkermes, INC. | $72.80 | 2022-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $69.10 | 2022 | |
| Sunovion Pharmaceuticals INC. | $48.35 | 2021 | |
| Ironshore Pharmaceuticals INC. | $37.84 | 2022 | |
| Axsome Therapeutics, INC. | $21.65 | 2023 | Auvelity |
| Indivior INC. | $21.61 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.53 | 2024 | Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Seal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.